2024ÄêÊÀ½ç·Î°©´ó»á£¨WCLC£©½«ÓÚµ±µØÊ±¼ä9ÔÂ7ÈÕÖÁ10ÈÕÔÚÃÀ¹úÊ¥µØÑǸçÕÙ¿ª¡£ÔÚ´ó»á¹«²¼µÄ¡°×îÐÂÍ»ÆÆÕªÒª(Late Breaking Abstract£¬LBA)¡±Ãûµ¥ÖУ¬µÏÍþÖÆµÏÍþ¹ú¼ÊÔÑд´ÐµÏÍþ¹ú¼Ê°¢ÃÀÌæÄá¼°±¸ÊܹØ×¢µÄ¹ÜÏß²úÆ·HS-20093ƾ½èÓÅÒìµÄÑо¿½á¹û˫˫ÈëÑ¡£»°¢ÃÀÌæÄáÁíÓÐ12ƪ´´Ð³ɹûÈëÑ¡±¾½ì´ó»á£¬ÄÚÈݺ¸Çи¨Öú¡¢¸¨Öú¡¢ÁªºÏ»¯ÁÆ¡¢ÁªºÏ·ÅÁÆ¡¢ÄÔ×ªÒÆµÈÁìÓò¡£
Part 1£º×îÐÂÍ»ÆÆÕªÒª£¨LBA£©
¡¾1.1¡¿ Aumolertinib Maintenance after Chemoradiotherapy in stage ¢ó Non-Small-Cell Lung Cancer: Interim Results of the phase ¢ó study (POLESTAR)
°¢ÃÀÌæÄáÓÃÓÚ·Å»¯Áƺó¢óÆÚ·ÇСϸ°û·Î°©µÄά³ÖÖÎÁÆ£º¢óÆÚÑо¿£¨POLESTAR£©µÄÖÐÆÚ½á¹û
¡¾1.2¡¿ Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase ¢ñ Study (ARTEMIS-001)
Ò»Ïî¶àÖÐÐÄ¡¢¢ñÆÚÑо¿£¨ARTEMIS-O01£©ÖÐ HS-20093 ÖÎÁƹ㷺ÆÚСϸ°û·Î°©µÄÁÆÐ§ºÍ°²È«ÐÔ
×÷ÕߣºÍõ½à£¨Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£©
Part 2£ºÃÔÄã¿ÚÍ·±¨¸æ
¡¾2.1¡¿ Aumolertinib as adjuvant therapy in resectable ¢ñ-¢ó EGFR-mutant NSCLC : also effective in patients with high-risk relapse factors
°¢ÃÀÌæÄá×÷Ϊ¿ÉÇгý¢ñ-¢óÆÚEGFRÍ»±äNSCLC µÄ¸¨ÖúÖÎÁÆ£º¶Ô¾ßÓи´·¢¸ßΣÒòËØ»¼ÕßÒ²ÓÐЧ
×÷ÕߣºÒ¦½¡£¨¼ªÁÖÊ¡ÈËÃñÒ½Ôº£©
Part 3£ºÑо¿Éè¼Æ
¡¾3.1¡¿ MRD guiding treatment after Aumolertinib induction therapy for EGFRm+ stage ¢ó NSCLC in the MDT diagnostic model (APPROACH)
MDTÕïÁÆÄ£Ê½ÏÂEGFRÍ»±äÑôÐÔ²»¿ÉÇгý¢óÆÚ·ÇСϸ°û·Î°©¾°¢ÃÀÌæÄáÓÕµ¼ÖÎÁƺóMRD¶¯Ì¬¼à²âÖ¸µ¼ÖÎÁƾö²ßµÄÓÐЧÐԺͰ²È«ÐÔÑо¿£ºÒ»Ï·ÅÐÔ¡¢¶àÖÐÐÄ¡¢¢óÆÚÁÙ´²Ñо¿
×÷ÕߣºÖÜÇå¡¢ÎâÒ»Áú£¨¹ã¶«Ê¡ÈËÃñÒ½Ôº£©
¡¾Öйúר³¡ÌÖÂÛ±Ú±¨¡¿
¡¾3.2¡¿ Efficacy and safety of Aumolertinib with radiotherapy in the treatment of unresectable locally advanced EGFR-mutant NSCLC: a phase ¢ò study
°¢ÃÀÌæÄáÁªºÏ·ÅÁÆÖÎÁƲ»¿ÉÇоÖÍíÆÚµÄEGFRÍ»±äNSCLCµÄÁÆÐ§ºÍ°²È«ÐÔ:Ò»Ïî¢òÆÚÑо¿
×÷ÕߣºÃÏÏ齿£¨É½¶«Ê¡Ö×ÁöÒ½Ôº£©
Part 4£ºÑо¿Êý¾Ý
¡¾4.1¡¿ Aumolertinib as neoadjuvant therapy for EGFRm+ NSCLC: a subcohort analysis of PURPOSE trial data updated
°¢ÃÀÌæÄáи¨ÖúÖÎÁÆEGFRÍ»±äNSCLC»¼ÕߣºPURPOSEÊÔÑéµÄ¶ÓÁзÖÎö
×÷Õߣº·½ÎÄÌΣ¨ÉϺ£ÊÐÐØ¿ÆÒ½Ôº£©
¡¾4.2¡¿ Aumolertinib in treatment-na?ve EGFR-mutant NSCLC patients with brain metastases: efficacy and safety data from the ARTISTRY
°¢ÃÀÌæÄáÖÎÁƳõÕï·ÇСϸ°û·Î°©£¨NSCLC£©°éÄÔ×ªÒÆµÄÓÐЧÐÔÓ밲ȫÐÔ£ºARTISTRYÑо¿¶ÓÁÐ1
×÷ÕߣºÕÅÏþ¾ê¡¢Íõ»Û¾ê£¨ºÓÄÏÊ¡Ö×ÁöÒ½Ôº£©
¡¾4.3¡¿ Aumolertinib with chemotherapy as first-line treatment in patients with EGFR-mutated advanced NSCLC: a real-world study
°¢ÃÀÌæÄáÁªºÏ»¯ÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äÍíÆÚNSCLC»¼ÕߣºÒ»ÏîÕæÊµÊÀ½çÑо¿
×÷ÕߣºÐí¼ÑÀö¡¢¹ùÈË»¨£¨½ËÕÊ¡ÈËÃñÒ½Ôº£©
¡¾4.4¡¿ Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage ¢ñ NSCLC with multiple high-risk factors
°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÍ»±ä°é¶àÖØ¸ßΣÒòËØµÄ¢ñÆÚNSCLC
×÷ÕߣºÎâÆë·É£¨Î÷°²½»´óÒ»¸½Ôº£©
¡¾4.5¡¿ Safety and efficacy of cranial radiotherapy in combination with Aumolertinib in EGFR-mutant NSCLC patients with brain metastases
EGFRÍ»±ä·ÇСϸ°û·Î°©ÄÔ×ªÒÆ°¢ÃÀÌæÄáÁªºÏ¾«×¼·ÅÁƵÄÁÆÐ§ºÍ°²È«ÐÔ
×÷Õߣº±Ï骣¨Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£©
¡¾4.6¡¿ Adjuvant Aumolertinib in resected stage I EGFR-mutated NSCLC: prospectively evaluating efficacy in residual GGN lesions
°¢ÃÀÌæÄáÖÎÁÆEGFRÍ»±äIÆÚ·Î°©ÇгýÊõºó²ÐÁô·ÎÄ¥²£Á§½á½Ú
×÷Õߣº»Æ³ç±ê£¨Ìì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº£©
¡¾4.7¡¿ Adjuvant Aumolertinib in patients with completely resected, stage ¢ñA2-¢óA Non-Small-Cell Lung Cancer with uncommon EGFR mutations
°¢ÃÀÌæÄḨÖúÖÎÁÆ¢ñA2-¢óAÆÚº±¼ûEGFRÍ»±äNSCLC»¼Õß
×÷Õߣººú¼á£¨Õã½´óѧҽѧԺ¸½ÊôµÚÒ»Ò½Ôº£©
¡¾4.8¡¿ Efficacy and safety of Aumolertinib in stage ¢ñB-¢óA NSCLC after R0 resection and the correlation between efficacy and postoperative MRD status
°¢ÃÀÌæÄáÊõºó¸¨ÖúÖÎÁÆR0ÇгýµÄ¢ñB-¢óAÆÚNSCLC»¼ÕßµÄÁÆÐ§ºÍ°²È«ÐÔÒÔ¼°ÊõºóMRDÓëÁÆÐ§Ïà¹ØÐÔµÄÑо¿
×÷ÕߣºÑîʤÀû£¨·ðɽÊеÚÒ»ÈËÃñÒ½Ôº£©
Part 5£º²¡ÀýϵÁÐ
¡¾5.1¡¿ High-dose Aumolertinib combined intrathecal chemotherapy for the treatment of EGFR-mutated NSCLC with leptomeningeal metastasis
¸ß¼ÁÁ¿°¢ÃÀÌæÄáÁªºÏÇÊÄÚ»¯ÁÆÖÎÁÆEGFRÍ»±äNSCLC°éÄÔÄ¤×ªÒÆ
×÷ÕߣºÍõΰ£¨ÖØÇì´óѧ¸½ÊôÈýϿҽԺ£©
µÏÍþÖÆµÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖÆµÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀɵÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò£¬ÖÂÁ¦ÓÚͨ¹ý³ÖÐø´´ÐÂÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£½ØÖÁĿǰ£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬´´ÐµÏÍþ¹ú¼ÊÓªÊÕÕ¼±ÈÒÑÍ»ÆÆÖÁ67.9%¡£¹«Ë¾Á¬Ðø¶àÄêλ¾ÓÈ«ÇòÖÆµÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖØµã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£
ǰհÐÔ˵Ã÷
±¾ÎÄÖ¼ÔÚÌṩÓйء°µÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¡±»òÆä×Ó¹«Ë¾µÈ¹ØÁª·½£¨Í³³Æ¡°¹«Ë¾¡±£©µÄÏà¹ØÐÅÏ¢£¬²»¹¹³É¹«Ë¾ÐÅÏ¢Åû¶»òͶ×ÊÍÆ¼ö¡£
±¾ÎÄËù·¢²¼µÄÐÅÏ¢ÖпÉÄÜ»á°üº¬Ä³Ð©Ç°Õ°ÐÔ±íÊö£¬ÀýÈçÉæ¼°ÒµÎñºÍ²úƷǰ¾°£¬»ò¹«Ë¾¼Æ»®¡¢ÈÏÖª¡¢Ô¤ÆÚ¼°²ßÂÔ¡£ÕâЩ±íÊöÊǽ¨Á¢ÔÚÍÆ²âÐÔ¼ÙÉèµÄÊý¾Ý»ù´¡ÉϵÄÔ¤²â£¬²¢·ÇÊǶÔδÀ´·¢Õ¹µÄ±£Ö¤£¬ÒòÆäÐÔÖÊʹȻ¾ùÊÜÏà¹Ø·çÏպͲ»È·¶¨ÒòËØÓ°Ï죬ÆäÖв¿·Ö»¹²»Êܹ«Ë¾¿ØÖÆÇÒÄÑÒÔÔ¤ÁÏ£¬Í¶×ÊÕß½øÐÐͶ×ʾö²ßʱӦ½÷É÷ʹÓá£ÔÚʹÓá°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°ÆÚÍû¡±¼°ÆäËûÀàËÆ´ÊÓï½øÐбíÊöʱ£¬·²Ó빫˾ÓйصÄÐÅÏ¢±íÊö£¬¾ùÊôÓÚǰհÐÔ±íÊö¡£¹«Ë¾²¢ÎÞÒåÎñ¸üлòÐÞ¸ÄÕâЩǰհÐÔ±íÊö£¬¹«Ë¾¡¢¹«Ë¾¶Ê¡¢¹ÍÔ±¡¢´úÀí¸Å²»³Ðµ£ÒòÈκÎǰհÐÔ±íÊö²»ÄÜʵÏÖ»ò±ä³É²»ÕýÈ·¶øÒýÖµÄÈκÎÔðÈΡ£
±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟ巢²¼Ö®ÈÕ£¬ÎÞÂÛÊÇ·ñ³öÏÖÐÂ×ÊÁÏ¡¢Î´À´Ê¼þ»òÆäËûÇé¿ö£¬³ý·Ç·¨ÂÉÒªÇ󣬹«Ë¾²¢ÎÞÔðÈλòÒåÎñ¸üлòÐ޸ĸõÈÐÅÏ¢¡£Í¶×ÊÕßÒ˲ÎÕÕµÏÍþÖÆµÏÍþ¹ú¼Ê£¨03692.HK£©¹«¸æ¼°²Æ±¨£¬ÒÔ»ñÈ¡½öÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢¡£